On March 28, 2022, Ofir Levi resigned as a member of the Board of Directors of Vallon Pharmaceuticals, Inc. (the Company) and as Chairman of the Board. Dr. Levi's decision to resign was not due to any disagreement with the Company or its management on any matter related to the operations, policies or practices of the Company or its management, but rather, was due to personal reasons.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4007 USD | -1.18% | +2.72% | -94.02% |
Apr. 16 | GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments | MT |
2023 | Vallon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
- Stock Market
- Equities
- GRI Stock
- News GRI BIOPAR
- Vallon Pharmaceuticals, Inc. Announces Resignation of Ofir Levi as Member of the Board of Directors and as Chairman of the Board